EA201690464A1 - Применение композиции, содержащей микроорганизмы, для увеличения образования масляной кислоты, фолиевой кислоты или ниацина в кишечнике и/или уменьшения образования янтарной кислоты в кишечнике - Google Patents

Применение композиции, содержащей микроорганизмы, для увеличения образования масляной кислоты, фолиевой кислоты или ниацина в кишечнике и/или уменьшения образования янтарной кислоты в кишечнике

Info

Publication number
EA201690464A1
EA201690464A1 EA201690464A EA201690464A EA201690464A1 EA 201690464 A1 EA201690464 A1 EA 201690464A1 EA 201690464 A EA201690464 A EA 201690464A EA 201690464 A EA201690464 A EA 201690464A EA 201690464 A1 EA201690464 A1 EA 201690464A1
Authority
EA
Eurasian Patent Office
Prior art keywords
acid
formation
niacin
intestinal
increase
Prior art date
Application number
EA201690464A
Other languages
English (en)
Other versions
EA036534B1 (ru
Inventor
Андреа Биффи
Руджеро Росси
Вальтер Фьоре
Симоне Доменико Гульельметти
Original Assignee
Софар С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Софар С.П.А. filed Critical Софар С.П.А.
Publication of EA201690464A1 publication Critical patent/EA201690464A1/ru
Publication of EA036534B1 publication Critical patent/EA036534B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/165—Paracasei
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к применению композиции, содержащей бактерии, для увеличения образования масляной кислоты, фолиевой кислоты или ниацина и/или для уменьшения образования янтарной кислоты в кишечнике. Более того, настоящее изобретение относится к применению указанной композиции для лечения и/или предотвращения бутират- и/или сукцинат-зависимого патологического состояния кишечника, в частности для лечения и/или предотвращения воспаления кишечника, диареи, язвенного колита или кишечных колопатий.
EA201690464A 2013-09-06 2014-09-05 Применение композиции, содержащей бактериальный штамм lactobacillus paracasei dg, в лечении и/или предотвращении патологического состояния, чувствительного к лечению масляной кислотой и/или янтарной кислотой EA036534B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001467A ITMI20131467A1 (it) 2013-09-06 2013-09-06 Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
PCT/IB2014/064285 WO2015033305A1 (en) 2013-09-06 2014-09-05 Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acid

Publications (2)

Publication Number Publication Date
EA201690464A1 true EA201690464A1 (ru) 2016-08-31
EA036534B1 EA036534B1 (ru) 2020-11-20

Family

ID=49354800

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690464A EA036534B1 (ru) 2013-09-06 2014-09-05 Применение композиции, содержащей бактериальный штамм lactobacillus paracasei dg, в лечении и/или предотвращении патологического состояния, чувствительного к лечению масляной кислотой и/или янтарной кислотой

Country Status (25)

Country Link
US (2) US11839634B2 (ru)
EP (1) EP3041489B1 (ru)
JP (1) JP6651450B2 (ru)
CN (2) CN115804798A (ru)
AU (1) AU2014316688B2 (ru)
BR (1) BR112016005059B1 (ru)
CA (1) CA2923392C (ru)
CY (1) CY1123127T1 (ru)
DK (1) DK3041489T3 (ru)
EA (1) EA036534B1 (ru)
ES (1) ES2805471T3 (ru)
HK (1) HK1224192A1 (ru)
HR (1) HRP20201065T1 (ru)
HU (1) HUE050146T2 (ru)
IL (2) IL244392B (ru)
IT (1) ITMI20131467A1 (ru)
LT (1) LT3041489T (ru)
ME (1) ME03805B (ru)
MX (1) MX2016002765A (ru)
PL (1) PL3041489T3 (ru)
PT (1) PT3041489T (ru)
RS (1) RS60518B1 (ru)
SG (2) SG11201601662SA (ru)
SI (1) SI3041489T1 (ru)
WO (1) WO2015033305A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HUE044617T2 (hu) 2015-06-15 2019-11-28 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
GB201704525D0 (en) 2017-03-22 2017-05-03 Central Glass Co Ltd Vehicle glass window with electrical connector soldered by lead-free solder
EP3630137B1 (en) * 2017-05-22 2023-05-17 4D Pharma Research Limited Compositions comprising bacterial strains
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SI3638271T1 (sl) 2017-06-14 2021-01-29 4D Pharma Research Limited Sestavki, ki vsebujejo bakterijske seve
PL3600364T3 (pl) 2017-06-14 2021-01-11 4D Pharma Research Limited Kompozycje zawierające szczep bakteryjny z rodzaju megasphaera i ich zastosowania
IT201700101704A1 (it) * 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
AU2018378419A1 (en) * 2017-12-06 2020-07-09 Lac2biome S.r.l. Composition based on probiotics and uses thereof
MX2020007619A (es) * 2018-01-17 2020-09-28 Consorcio Centro De Investig Biomedica En Red M P Intervenciones dirigidas, encaminadas a reducir los niveles de succinato circulante en un sujeto, y kits y metodo para determinar la eficacia de dichas intervenciones.
CN110358712B (zh) * 2019-07-26 2021-11-09 浙江一鸣食品股份有限公司 一种乳酸菌组合物及其应用
CN110358714A (zh) * 2019-08-01 2019-10-22 浙江一鸣食品股份有限公司 一种高产叶酸的乳酸菌组合物
CN110669697B (zh) * 2019-10-31 2022-07-15 微康益生菌(苏州)股份有限公司 一种高产短链脂肪酸的干酪乳杆菌、培养方法及其应用
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517363A (ja) 1991-07-11 1993-01-26 Yakult Honsha Co Ltd 抗炎症剤及びそれを含有する化粧料
US5716615A (en) 1992-02-10 1998-02-10 Renata Maria Anna Cavaliere Vesely Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
CN1066926C (zh) 1996-04-08 2001-06-13 钟春燕 将椰子水发酵制作的食用纤维及其生产方法
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CZ9900769A3 (cs) 1999-03-04 2000-10-11 Petr Ing. Drsc. Hušek Použití špičky s filtrem k vytvoření sloupce sorbentu s definovaným objemem v prostoru pod filtrem
US20020090416A1 (en) 1999-03-09 2002-07-11 Philip Connolly Method of enhancing absorption and utilization of protein
IT1307850B1 (it) * 1999-03-15 2001-11-19 Italmed Di Galli Giovanna E Pa Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio
EP1145643A1 (en) 2000-04-10 2001-10-17 Phillip Connolly Improved milk protein concentrate
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
RU2182008C1 (ru) 2000-10-20 2002-05-10 Самойленко Игорь Иннокентьевич Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии
PE20030284A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
FI20020078A (fi) * 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6881419B2 (en) * 2002-04-09 2005-04-19 William E. Lovett Vitamin formulation for enhancing bone strength
AU2002309180A1 (en) 2002-04-24 2003-11-10 Medicarb Ab Composition and kit for the treatment of inflammatory bowel diseases
DE60330781D1 (de) * 2002-08-06 2010-02-11 Danisco Anwendung von lactobacillus zur herstellung von exopolysacchariden in nahrungsmittel und pharmazeutische zusammensetzungen
AU2002951270A0 (en) 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
WO2005001109A2 (en) 2003-05-06 2005-01-06 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Methods and compositions to detect microbes in fecal samples
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
CA2557543A1 (en) 2004-02-27 2005-09-09 Stichting Laboratorium Voor Infectieziekten Method for detecting a microorganism in a fecal specimen
EP1722804B1 (en) 2004-03-04 2015-01-21 E-L Management Corp. Skin treatment method with lactobacillus extract
CA2587670A1 (en) 2004-11-01 2006-05-11 George Mason University Compositions and methods for diagnosing colon disorders
WO2006108008A2 (en) * 2005-04-06 2006-10-12 Novartis Ag A method and composition for nutritionally improving glucose control and insulin action
FI20051319L (fi) 2005-12-22 2007-06-23 Cyflo Oy Menetelmä eläimen ja/tai ihmisen ravitsemuksen ja hyvinvoinnin ja eläinten tuottavuuden seuraamiseksi ja kehittämiseksi
CN1840206A (zh) 2006-01-19 2006-10-04 上海交通大学 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法
JP4590573B2 (ja) 2006-02-21 2010-12-01 国立大学法人富山大学 感染症起因菌の迅速同定方法
CN101415731B (zh) 2006-02-24 2011-11-02 丘比株式会社 新型低分子透明质酸和/或其盐以及使用其的化妆品、医药组合物和食品组合物
US20100166721A1 (en) 2006-06-09 2010-07-01 Fabiola Masri Probotic compositions and uses thereof
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
US20080081035A1 (en) * 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
CA2673120C (en) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation A dry food product containing live probiotic
EP1972208A1 (en) * 2007-03-16 2008-09-24 Kirin Holdings Kabushiki Kaisha Composition for improving intestinal microflora
BRPI0809454A2 (pt) 2007-03-27 2014-09-09 Procter & Gamble Métodos e kits para a administração de probióticos
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
PT2173196E (pt) * 2007-07-06 2011-05-23 Nutricia Nv Uso de probi?ticos e fibras para a diarreia
US8193155B2 (en) 2009-02-09 2012-06-05 Elc Management, Llc Method and compositions for treating skin
US20090098088A1 (en) 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
CN101240315A (zh) 2008-02-21 2008-08-13 上海交通大学 检测药物防癌效果的非损伤性分子方法
CA2721981A1 (en) 2008-05-01 2009-11-05 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
WO2010008272A1 (en) 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
JP2010161944A (ja) 2009-01-13 2010-07-29 Syngen Biotech Co Ltd 新型カゼイ菌の亜種（ｓｇ９６）及びこれを含有する菌抑制組成物及びその用途
RU2011139211A (ru) 2009-03-05 2013-04-10 Пробиотикал С.п.А. Бактериальные штаммы, обладающие высокой противовоспалительной активностью
WO2010103132A1 (es) 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
US20120177650A1 (en) 2009-09-23 2012-07-12 Borody Thomas J Therapy for enteric infections
JP6006117B2 (ja) * 2009-11-12 2016-10-12 ネステク ソシエテ アノニム 腸内微生物叢バランス及び健康を促進するための栄養組成物
BR112012015033B1 (pt) 2009-12-22 2020-11-03 Probi Ab uso de uma composição não fermentada
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
ITUD20100112A1 (it) 2010-06-09 2011-12-10 Farma Derma S R L Preparazione per uso vaginale e rettale e relativo procedimento di produzione
WO2012135499A1 (en) 2011-03-31 2012-10-04 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
WO2012154738A1 (en) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition and method to improve intestinal health
EP3366143A1 (en) 2011-06-20 2018-08-29 H.J. Heinz Company Brands LLC Probiotic compositions and methods
GB201219873D0 (en) 2012-11-05 2012-12-19 Multigerm Uk Entpr Ltd Diverticulitis treatment
CN102919922A (zh) 2012-11-08 2013-02-13 黑龙江省轻工科学研究院 一种复合益生菌发酵蓝莓果汁粉的制备方法
JP2016511272A (ja) * 2013-03-05 2016-04-14 レイクスユニフェルシテイト フローニンゲン 炎症を抑制するためのフィーカリバクテリウム・パラウスニッチィーｈｔｆ−ｆ（ｄｓｍ２６９４３）の使用
JP6643984B2 (ja) 2013-07-02 2020-02-12 オーストリアノヴァ シンガポール プライベート リミテッド カプセル化細胞を凍結乾燥する方法、凍結乾燥されたカプセル化細胞、凍結乾燥されたカプセル化細胞を含む組成物、ならびに、そのような細胞および組成物の使用
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
ITMI20131473A1 (it) 2013-09-06 2015-03-07 Sofar Spa Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
WO2015172191A1 (en) 2014-05-12 2015-11-19 Medlab Ip Pty Ltd Probiotic compositions and uses thereof for treatment of obesity-related disorders
DK2990045T3 (en) 2014-08-26 2017-02-13 Chr Hansen As Bifidobacterium animalis subsp. lactis for use in reducing abdominal pain in a postmenopausal woman
WO2017195182A1 (en) 2016-05-13 2017-11-16 Sofar S.P.A. Use of probiotics for improving protein absorption
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
RU2744271C2 (ru) 2016-12-16 2021-03-04 Компани Жервэ Данон Пробиотическая композиция, содержащая штаммы Lactobacillus rhamnosus и Lactobacillus paracasei
WO2019019961A1 (zh) 2017-07-26 2019-01-31 海思科医药集团股份有限公司 防治消化道和/或皮肤反应的菌群及其应用
IT201700101704A1 (it) 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
AU2018378419A1 (en) 2017-12-06 2020-07-09 Lac2biome S.r.l. Composition based on probiotics and uses thereof
CN108743851A (zh) 2018-08-09 2018-11-06 深圳市博奥生物科技有限公司 一种复合益生菌粉的制备方法及复合益生菌粉
IT201900016811A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900016850A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e estratti di bacche e loro uso come antinfiammatori
IT201900016805A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900016865A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e loro uso come antinfiammatori
IT201900020422A1 (it) 2019-11-05 2021-05-05 Sofar Spa Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems

Also Published As

Publication number Publication date
HUE050146T2 (hu) 2020-11-30
SI3041489T1 (sl) 2020-10-30
EP3041489A1 (en) 2016-07-13
IL244392B (en) 2019-09-26
IL269107B (en) 2021-01-31
CY1123127T1 (el) 2021-10-29
AU2014316688B2 (en) 2020-02-27
DK3041489T3 (da) 2020-07-20
LT3041489T (lt) 2020-09-25
ME03805B (me) 2021-04-20
SG11201601662SA (en) 2016-04-28
IL244392A0 (en) 2016-04-21
AU2014316688A1 (en) 2016-03-24
ES2805471T3 (es) 2021-02-12
US20160296569A1 (en) 2016-10-13
US20240050497A1 (en) 2024-02-15
BR112016005059A2 (pt) 2017-11-21
PT3041489T (pt) 2020-07-16
CN115804798A (zh) 2023-03-17
ITMI20131467A1 (it) 2015-03-07
WO2015033305A1 (en) 2015-03-12
SG10202001331PA (en) 2020-04-29
US11839634B2 (en) 2023-12-12
BR112016005059B1 (pt) 2022-01-04
HRP20201065T1 (hr) 2020-12-11
PL3041489T3 (pl) 2020-11-02
RS60518B1 (sr) 2020-08-31
CA2923392C (en) 2023-01-03
JP2016529309A (ja) 2016-09-23
CA2923392A1 (en) 2015-03-12
EA036534B1 (ru) 2020-11-20
MX2016002765A (es) 2016-08-03
CN105916513A (zh) 2016-08-31
JP6651450B2 (ja) 2020-02-19
HK1224192A1 (zh) 2017-08-18
IL269107A (en) 2019-11-28
EP3041489B1 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
EA201690464A1 (ru) Применение композиции, содержащей микроорганизмы, для увеличения образования масляной кислоты, фолиевой кислоты или ниацина в кишечнике и/или уменьшения образования янтарной кислоты в кишечнике
BR112018067689A2 (pt) composições compreendendo cepas bacterianas do gênero blautia para tratar a hipersensibilidade visceral
MA41013A (fr) Compositions comprenant des souches bactériennes
EA201691534A1 (ru) Лечение устойчивых угрей
CY1122305T1 (el) Ενωσεις υδροξαζολης υδροξαμικου οξεος ως αναστολεις lpxc
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201890239A3 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
BR112015030203A2 (pt) moléculas pequenas inibidores da fibrose
UA107423C2 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
BR112015027536A8 (pt) composição compreendendo bactérias ácidas lácticas para utilização no tratamento preventivo e/ou curativo de cistite recorrente.
EA201591122A1 (ru) Гетероциклическое соединение
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
BR112017014649A2 (pt) ?isolado intestinal humano, e, composição?
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201790442A1 (ru) Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae
CY1117620T1 (el) Τριτοκαλινη για χρηση στην αντιμετωπιση της κυστικης ινωσης
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201790912A1 (ru) Гетероциклическое соединение
MY191884A (en) Oil purification process
MA46269A (fr) Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r
MX2017010357A (es) Derivados novedosos de n-acil-arilsulfonamida como inhibidores de aminoacil acido ribonucleico de transferencia (arnt) sintetasa.
PH12016501059A1 (en) A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
EP2941255A4 (en) METHOD FOR TREATING OR RELIEVING A DISEASE CAUSED OR AGGRAVATED BY MICROORGANISMS